Capital International’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-6,757
Closed -$2M 177
2019
Q4
$2M Sell
6,757
-4,340
-39% -$1.2M 0.21% 106
2019
Q3
$2.58M Buy
11,097
+4,944
+80% +$1.15M 0.39% 76
2019
Q2
$1.44M Sell
6,153
-1,673
-21% -$386K 0.34% 82
2019
Q1
$1.85M Buy
7,826
+1,177
+18% +$371K 0.44% 62
2018
Q4
$2M Buy
6,649
+1,165
+21% +$372K 0.54% 56
2018
Q3
$1.94M Buy
5,484
+3,064
+127% +$1.05M 0.6% 44
2018
Q2
$702K Buy
+2,420
New +$680K 0.12% 142

Other funds holding BIIB

Capital International's BIIB Position: Q1 2020 in Review

Capital International sold out of Biogen (BIIB) in Q1 2020, closing a stake of 6,757 shares — an estimated $2M sold.

Capital International first reported a position in BIIB in Q2 2018 and held it in 7 quarters. The position peaked at $2.58M in Q3 2019. 1,098 funds tracked by Wall St. Rank hold BIIB as of Q1 2020.

  • Capital International reported no remaining Biogen position as of Q1 2020 after selling out during the quarter.
  • Capital International sold 6,757 Biogen shares in Q1 2020, an estimated $2M.
  • Capital International first reported a position in Biogen in Q2 2018 and held it in 7 quarters.
  • Capital International's Biogen position peaked at $2.58M in Q3 2019.
  • 1,098 funds tracked by Wall St. Rank held Biogen as of Q1 2020.

Based on Capital International's 13F filing for Q1 2020, filed 15 May 2020.